Here’s how L.A.’s Curative Plans to Move Saliva-Based COVID-19 Testing to Other U.S. Cities

Rachel Uranga

Rachel Uranga is dot.LA's Managing Editor, News. She is a former Mexico-based market correspondent at Reuters and has worked for several Southern California news outlets, including the Los Angeles Business Journal and the Los Angeles Daily News. She has covered everything from IPOs to immigration. Uranga is a graduate of the Columbia School of Journalism and California State University Northridge. A Los Angeles native, she lives with her husband, son and their felines.

Here’s how L.A.’s Curative Plans to Move Saliva-Based COVID-19 Testing to Other U.S. Cities

Fred Turner, the 25-year-old founder of Curative Inc., is the man behind L.A.'s push to bring universal testing to the region. But, he has bigger plans.

Turner, an Oxford dropout, just landed a deal with the Air Force to test military worldwide and he's now eyeing national expansion for his startup. By the end of this month, the company he started months ago is expected to pump out more than a million test kits a week.

"We are a strange company because our goal is to essentially put ourselves out of business," Turner said.


Turner, who was named UK Young Engineer of the Year at age 17 when he built a DNA machine from his bedroom to figure out why his brother had red hair and he had brown hair, turned his focus to coronavirus in January. He upended his life as head of Shield Bio, which sought to eliminate sepsis, and moved to Southern California after a local venture capitalist connected him with a lab that he could build out for COVID-19 testing.

Curative Inc. was born.

Curative, Inc. Founder Fred Turner is the man behind L.A.'s push to bring universal testing to the region.

For weeks he lived in hotels as he created what has become the backbone of testing in America's second largest city. The company, one of the few saliva-based tests that have gotten emergency approvals from the FDA, has a 10% false negative rate, according to their own non-peer reviewed studies. Turner argues the rate is better than most of the nasal swab testing out there and oral tests, which can be self-administered, are the only way the country can reopen quickly.

He is now operating two labs, one in San Dimas another in Washington D.C., with plans for several more across the nation. Meanwhile, the rest of the country is watching to see if Los Angeles' promise of universal testing meets the expectations with some already complaining about the difficulty of securing an appointment.

dot.LA: Curative is responsible for 95% of Los Angeles COVID-19 tests. Can you meet the demand for universal testing?

Curative, Inc. Founder Fred Turner: We will be able to fulfill demand. There's more infrastructure that needs to be put in place. With the collection site, the mayor's office has been working hard to scale those up and make sure that the collection site infrastructure is in place. On the lab side, we definitely have enough capacity to serve the area.

In (the San Dimas) lab we have capacity for about 20,000 per day. We're going to be scaling this lab up to 30,000 over the next week or so, eventually, probably slightly more than that.

Ultimately, the goal is to do as many tests as we need to reopen the country and I think we've had many different estimates of how many that might be. I've heard estimates (that it will take) as high as five million tests a day to reopen, but the current supply chain is nowhere near going to be able to keep up with that. The next goal we are shooting for is a million tests a week by about mid-May, end of May.

If we're testing more people will that strain the turnaround time? Right now, I understand it's about 24 to 72 hours. Can you take it down to several hours or even minutes?

We are always aiming to push it down. I think it can be pushed under 24 hours, but we tend to focus more on scaling it up at that point. I think 24 hours is around optimal as you bring on more capacity. We're obviously being careful to match the capacity coming into the lab against the turnaround.

Curative is one of the few companies that the FDA has provided emergency approval for use of a saliva test. Do you think this is the answer to universal testing nationally?

Oral fluids is the technical term, which is slightly different from saliva. Our protocol involves having the person cough first, which releases virus from the upper and lower respiratory tract. Some of that is then caught in the saliva, and also viruses in the saliva. The idea is you're effectively sampling multiple sites at once, which we think gives a slight increase in the sensitivity of the testing.

Self-collected sampling has got to be the way forward. There's just no way that we can do a million nasal pharyngeal swabs, or we call them 'brain swabs,' it's just not practical. We don't have the medical staff, and as a country we just can't do that many swabs. And so the way forward is going to be self collection. That's the only thing we can do at scale.

Covid-19 Oral Fluid Test Kit Instructions www.youtube.com

Curative recently secured a contract with the Department of Defense. What's next?

We haven't settled on the exact number, but we will be in a large number of states. That is the plan, building out the infrastructure for this kind of testing. We can take the L.A. model and scale it across the country. We have a version of the drive-thru software that other cities and states can take. We have all the training material. We have a team that fly around the country setting up these drive-thru sites. We have really tried to make a plug-and-play package where cities and states that want to launch drive-thru testing, we have everything they need.

Is Los Angeles a testing ground and a proving ground for national efforts?

Yeah, I think Mayor Garcetti has definitely demonstrated what can be done if the city moves very quickly to build out the infrastructure, I do think the drive-thru testing, walk through testing is going to be an essential component of this.

It's just much faster to get the samples to the lab than shipping it out and then shipping it back again. The infrastructure piece is critical for getting these tests out there and we're working with several other states now on building out a similar infrastructure. Some of them have existing programs that we would be plugging into and expanding, and some of them are looking to roll out their own similar programs. You can test a lot more people with the oral tests with far fewer staff.

What are the challenges with the supply chain in terms of making your tests more widely available?

We need more plastic, more robots, more people. Most of the components that go into these tests are just already maxed out in their production capacity. And so we've been throwing online a bunch of internal production, such as injection molding to make our swab kit tubes, as well as bringing on other sources of similar materials that are not being used for COVID-19 testing and validating them for COVID. So for the swabs, for example, we use a swab type that is usually used for testing clean rooms. It works just as well for COVID testing, but nobody else is using it for that purpose.

We don't want to be competing with other people, stopping them from getting access to resources. We want to bring on new supply so it's not a zero- sum game, and the total amount of tests will increase. But, I think distribution is going to be a bigger bottleneck over the next month. Los Angeles has done a fantastic job in building out infrastructure and collection. That needs to happen now across the whole country.

What would it take to meet national demand?

It would take a network of multiple labs that we are calling gigalabs that can process 50,000 to 100,000 tests a day across the country and a significant scale up in the production of the physical components that go into the tests. We've been investigating lab sites in a few states, something central like Texas or Colorado.

Are you concerned that you have too high of a false negative rate at 10%?

All COVID tests will have false negative rates. In our studies, we demonstrated that the sensitivity is at least as good if not better than the nasal pharyngeal swab tests. So, there will definitely be false negatives as there will be in every test, but we think the data supports us having a low rate of false negatives. The sensitivity is about 90%.

When you include all patients, the nasal pharyngeal came in at about 79%. A new (non-peer reviewed) Yale study shows a higher sensitivity from saliva and all fluids than the nasal pharyngeal. I don't think we have the evidence to say that we're better yet, but we have the evidence to say that we're at least equivalent. The ease of doing oral tests and the accessibility is obviously significantly better. We're not using PPE. We're not exposing healthcare workers. It's just a much easier test to roll out that people can test themselves.

File:Florida National Guard (49677710741).jpg - Wikimedia Commons upload.wikimedia.org

At one point, Curative was attempting to roll out at-home testing and then had to pull back after FDA warnings. Will you be making home testing kits again?

I can't give a time estimate but we are actively working with the FDA right now. I think their concern is "can people adequately collect the sample, or will they do it wrong, and then get a negative test result," which is incorrect. Our plan is to use telemedicine observation. What we've seen in our clinical studies is that if you give people the chance to do it wrong, they will do it wrong. In fact when you have somebody observing, they read the instructions better and they collect a better sample. We're still working on the pricing and potentially looking at whether there is federal or state reimbursement for some of that testing and the potential of billing insurance.

Tracing technology has been promising. Do you have any plans to tie tests to these applications to testing?

We've had several conversations with contact tracing apps and we continue to work in collaboration with public health departments in their contract tracing efforts. Having the test is obviously one thing, but you have to use the information to actually stem the tide of COVID infection. And so, it is an essential step in working closely with various people.

I do like the app-based models where you obviously want to maintain people's privacy, but having people opt-in to share their location history if they test positive so you can contact nearby people.

What does Curative do once there's a vaccine? Are you obsolete?

The U.S. needs to maintain some kind of spare capacity so that next time we are not having to build all of this during a pandemic. But we are a strange company because our goal is to essentially put ourselves out of business. Ultimately, and I say this to everyone we hire, we don't know how long this will go on for. We want to provide as many tests as needed, but the goal is to end COVID and not be doing COVID testing anymore.

Curative took off in March when you arrived in Los Angeles from Silicon Valley, how has the journey been for you personally?

I don't have very much free time, but it's been a lot of fun to be able to work at this pace and have the support of people like the city, the mayor's office to really just do what is needed to scale this up. When we work with suppliers, and we say we're doing COVID testing, they just move heaven and earth to make things happen. It's been really inspiring to be a part of that push forward.

We are just pushing as hard as we can to scale up as fast as we possibly can and bring on as much testing as we can. The city opening up testing to everybody is kind of a culmination of that. We're making about 50,000 kits a day right now and we want to make that as widely available as we can. I would like to get a little more sleep.

The interview has been edited for clarity and brevity.

Correction: An earlier version of this story stated that Curative's saliva tests have a 10% false positive rate. In actuality, the tests have a 10% false negative rate.

Do you have a story that needs to be told? My DMs are open on Twitter @racheluranga. You can also email me.

From Your Site Articles
Related Articles Around the Web
https://twitter.com/racheluranga
rachel@dot.la
Netflix Doubles Down on LA

🔦 Spotlight

Hey Los Angeles.

Goodbye Coachella, hello Stagecoach. The desert doesn’t stay quiet for long, and neither does LA’s entertainment machine.

This week, that momentum showed up in a more permanent way.

Netflix is expanding its footprint in Los Angeles with a major move to take over and invest in Radford Studio Center, a historic production lot in Studio City. The company is planning a long-term transformation of the site, with upgrades to soundstages, production offices, and infrastructure designed to support the next generation of film and television production.

It’s a notable shift in a moment when production has been under pressure in California, with studios increasingly looking outside the state for cost advantages. Netflix going deeper in LA, and specifically into a legacy studio lot, signals a different kind of commitment. Not just to content, but to where that content actually gets made.

And it comes at a time when the streaming wars have matured. Growth is harder, budgets are tighter, and the focus has shifted from scale at all costs to efficiency and control. Owning or operating more of the production environment gives Netflix tighter control over timelines, costs, and output.

For Los Angeles, it’s a reminder of what still anchors the city. Even as AI, defense tech, and infrastructure startups continue to rise, entertainment remains one of the few industries where LA isn’t just competitive, it’s foundational.

Different headlines each week, but a consistent theme underneath them. Whether it’s power, autonomy, or content, the companies that matter are investing in the layers they don’t want to outsource.

And in this case, that layer is Hollywood itself.

Below are this week’s venture deals, fund announcements, and acquisitions across LA 👇


🤝 Venture Deals

    LA Venture Funds

    • UP Partners and Calm Ventures participated in Reliable Robotics’ $160M funding round, backing the autonomous aviation company as it advances pilotless flight technology for cargo and passenger aircraft. The round included a mix of new and existing investors, and the company plans to use the capital to accelerate certification efforts and expand deployment of its autonomous systems across commercial aviation. - learn more
    • Blue Heron Ventures participated in Tava Health’s $40M Series C, backing the company as it expands its tech-enabled mental health platform into a more integrated, full-stack system for providers, employers, and health plans. The round was led by Centana Growth Partners with participation from existing investors, and the company plans to use the funding to roll out new AI-powered tools and broaden access to care while reducing administrative friction across the system. - learn more
    • Vamos Ventures participated in Zócalo Health’s $15M Series A, backing the company as it scales its tech-enabled, community-based primary care model focused on high-need and underserved populations. The round was led by .406 Ventures with participation from existing and new investors, and the company plans to use the funding to expand its clinics and deepen partnerships with Medicaid programs as demand for accessible care grows. - learn more

    LA Exits
    • Studio71 has been acquired by Fixated as part of a broader deal in which German media company ProSiebenSat.1 sold its North American creator business, giving Fixated a large-scale network of creators and podcast operations and significantly expanding its footprint as it continues an aggressive roll-up strategy in the creator economy. The move signals continued consolidation in the space, with Fixated building a more vertically integrated platform across talent management, content production, and distribution. - learn more
    • Bonsai Health has been acquired by ModMed, bringing its AI-powered patient engagement platform into a broader healthcare software ecosystem. The deal is aimed at integrating Bonsai’s “agentic AI” capabilities into ModMed’s platform to automate patient outreach, fill care gaps, and improve scheduling across a network of nearly 50,000 providers. - learn more

      Download the dot.LA App

      A $26M Push Into Power in LA

      🔦 Spotlight

      Hello, Los Angeles.

      Coachella Weekend 2 is here, which usually means LA is either heading back to the desert or happily staying put this time around. Back in the city, the focus this week is less about music infrastructure and more about something far more critical, power.

      That’s where this week’s news comes in.

      Critical Loop, a Los Angeles-based energy startup, raised a $26 million Series A to tackle one of the least talked about bottlenecks in tech right now, grid interconnection. In simple terms, it’s the process of getting power to where it’s needed, and increasingly, that process is too slow to keep up.

      Critical Loop is building modular microgrid systems that can be deployed in days instead of years, giving industrial operators, data centers, and other energy-heavy users faster access to power without waiting on traditional grid upgrades. The round was led by Conifer Infrastructure Partners and Hanover, with participation from Better Ventures, Climate Capital, Adapt Nation Capital, and Cyrus Ventures.

      The timing here matters. Between AI infrastructure demands, electrification, and a broader push toward domestic energy resilience, power is quickly becoming a gating factor for growth. You can build the data center, the factory, or the next big thing, but none of it works if you can’t turn it on.

      That’s what makes companies like Critical Loop worth watching. They’re not building the flashiest part of the stack, but they’re solving for the piece everything else depends on.

      And in a city that knows a thing or two about scaling ambition quickly, that might be the most important layer of all.

      Below are this week’s fund announcements across LA 👇


      🤝 Venture Deals

      LA Venture Funds

      • Anthos Capital participated in Wealth.com’s $65M Series B, backing the AI-powered estate and tax planning platform as it scales across financial institutions. The oversubscribed round included new investors like Titanium Ventures and Pruven Capital alongside existing backers, and the company plans to use the funding to expand product development, pursue acquisitions, and grow its enterprise footprint as demand rises for AI-driven wealth management solutions. - learn more
      • Anamika Ventures participated in Sage Haven’s $3M pre-seed round, backing the AI-powered messaging and calling app designed to create a safer communication environment for kids. The round was led by Anamika Ventures alongside Fabric Ventures and a group of early-stage investors, as the company launches a platform focused on preventing cyberbullying through real-time AI moderation and parent oversight tools. - learn more
      • MANTIS Venture Capital participated in Factory’s $150M Series C, backing the AI startup as it builds autonomous software engineering systems for enterprise teams. The round was led by Khosla Ventures and included firms like Sequoia Capital, Blackstone, Insight Partners, and NEA, valuing the company at $1.5 billion. Factory plans to use the funding to invest further in product development and global expansion as demand grows for AI-driven tools that can automate large portions of the software development process. - learn more
      • Rebel Fund participated in Uplane’s $4.5M seed round, backing the AI startup as it looks to replace traditional marketing agencies with a platform that automates ad creation, testing, and budget optimization. The round was led by Play Ventures with participation from Y Combinator, 20VC, and Multimodal Ventures, and the company says its technology can improve return on ad spend by automating performance marketing workflows. - learn more
      • Alexandria Venture Investments and Presight Capital participated in Alloy Therapeutics’ $40M Series E, backing the biotech infrastructure company as it scales its AI-powered platform for drug discovery and development. The round included a mix of new investors like 8VC and JIC Venture Growth Investments alongside returning backers, valuing the company at $1 billion and underscoring continued interest in platforms that combine AI, data, and lab services across the biopharma lifecycle. - learn more
      • Finality Capital Partners participated in HYFIX’s $15M seed round, backing the semiconductor startup as it builds American-made chips designed to power drones and autonomous robots. The round was led by Craft Ventures with participation from Catapult Ventures, Multicoin Capital, and Sky Dayton, and the company is developing an integrated system-on-a-chip to replace fragmented hardware stacks and reduce reliance on foreign components. - learn more
      • Rainfall Ventures participated in Stendr’s $5.4M pre-seed round, backing the Norwegian defense tech startup as it builds an AI-native platform for drone detection and counter-drone operations. The round was co-led by Rainfall alongside ACME Capital and Skyfall, with additional participation from Antler, StartupLab, and other early-stage investors, and the company plans to use the funding to accelerate development of its multi-sensor technology and expand engineering capabilities. - learn more
      • Slauson & Co. participated in Slate Auto’s $650M funding round, backing the EV startup as it works to bring a lower-cost electric pickup truck to market. The round was led by TWG Global and comes as the Bezos-backed company prepares to begin production, targeting a more affordable segment of the EV market with a customizable truck expected to launch later this year. - learn more
      • Navitas Capital co-led Primepoint’s $10M seed round, backing the AI startup as it builds a platform that reads and connects complex construction drawings to streamline project workflows. The round also included investors like Penny Jar Capital, NextView Ventures, GS Futures, and Aglaé Ventures, and the company plans to use the funding to expand its platform and grow adoption among large commercial contractors. - learn more
      • Alexandria Venture Investments participated in Neomorph’s $100M Series B, backing the biotech company as it advances its molecular glue degrader platform targeting previously undruggable diseases. The round was led by Deerfield Management with participation from Regeneron Ventures, Longwood Fund, and Binney Street Capital, and the company plans to use the funding to support ongoing clinical trials and expand its broader drug development pipeline. - learn more

      Download the dot.LA App

      Hermeus Moves In. Uber Lines Up. LA Wins.

      🔦 Spotlight

      Hello, Los Angeles.

      This week’s transportation news says a lot about where LA is headed and who wants to build here.

      Start with Hermeus, which hit a $1 billion valuation after raising $350 million as it works on high-speed aircraft for defense applications. More notably for Los Angeles, the company is moving its headquarters to El Segundo, adding to the region’s growing aerospace and defense cluster. The round was led by Khosla Ventures, with participation from returning backers including Canaan Partners, Founders Fund, RTX Ventures, Bling Capital, and In-Q-Tel, along with new investors including Cox Enterprises, Socium Ventures, Destiny Tech100, Georgia Tech Foundation, 137 Ventures, and GSBackers.

      Then there’s Uber, which made two separate autonomous vehicle announcements that both put Los Angeles in the rollout map.

      The first is a partnership with Zoox, Amazon’s autonomous vehicle company. Uber said the service is expected to launch in Las Vegas in summer 2026 and then come to Los Angeles by mid-2027, giving riders the option to match with a Zoox robotaxi through the Uber app.

      The second is a new deal with MOIA America, which plans to deploy autonomous ID. Buzz vehicles on the Uber platform in Los Angeles by the end of 2026.

      Taken together, the message is pretty straightforward: LA is not just watching the future of transportation take shape, it is increasingly being used as the place to test it, scale it, and sell it. Hermeus is bringing its headquarters here as defense aviation regains momentum. Uber is lining up autonomous partners with Los Angeles as a target market. Different companies, different timelines, same conclusion: a meaningful share of the next transportation cycle is being built with LA in mind.

      Below are this week’s venture deals, fund announcements, and acquisitions across LA.


      🤝 Venture Deals

      LA Companies
      • PeakMetrics raised a $6M Series A to scale its AI-powered narrative intelligence platform, which helps organizations track how information spreads online and identify risks from misinformation and coordinated campaigns. The round was led by Moneta Ventures with participation from Techstars, Parameter Ventures, VITALIZE Venture Capital, and Gurtin Ventures, and the company plans to use the funding to enhance its real-time detection capabilities and expand adoption across enterprise and government customers. - learn more
      • Hybron raised a $25M seed round to scale its advanced carbon fiber composite manufacturing technology, which aims to produce high-performance components faster and at lower cost than traditional methods. The round was led by Marque Ventures with participation from a mix of venture firms and strategic investors, and the company plans to use the funding to expand manufacturing capacity, grow its team, and support increasing demand from aerospace and defense programs. - learn more

      LA Venture Funds

      • Emmeline Ventures participated in Osteoboost’s $8M funding round, backing the company as it expands access to its FDA-cleared wearable designed to treat low bone density in postmenopausal women. The round was led by Ambit Health Ventures with participation from Disrupt Health Impact Fund and others, and the company plans to use the capital to scale manufacturing, expand clinical research, and grow commercial adoption. - learn more
      • Bonfire Ventures led Juno’s $12M seed round, backing the AI-powered tax preparation platform as it aims to automate up to 90% of the manual work in tax filing for accounting firms. The round included participation from Impression Ventures and Xfund, and the company says its software can significantly reduce preparation time while keeping CPAs in the loop for review and advisory work. - learn more
      • Alexandria Venture Investments participated in Sidewinder Therapeutics’ $137M Series B, which will help fund the company’s push to bring its precision bispecific ADC cancer programs into the clinic. The round was co-led by Frazier Life Sciences and Novartis Venture Fund, and Sidewinder said it expects to advance its lead program into clinical development in 2027. - learn more
      • Slauson & Co. participated in Flora Fertility’s $5M seed round, backing the company as it builds what it describes as an individually owned fertility insurance platform that is not tied to an employer. The round was led by ManchesterStory, and Flora plans to use the funding to scale a model aimed at making fertility coverage more portable and accessible for consumers. - learn more
      • Mucker Capital participated in Fastrflow’s $375K early funding round, backing the startup as it builds a screen-aware AI copilot designed to assist students and professionals directly within their workflows. The company is focused on creating an assistant that can understand what’s on a user’s screen in real time to provide contextual help, positioning itself as a more integrated alternative to traditional standalone AI tools. - learn more

      LA Exits

      • Modern Animal has been acquired by Chewy, giving the pet e-commerce giant a much bigger physical veterinary footprint as it expands deeper into healthcare. The deal brings Chewy an additional 29 clinics, 24/7 virtual care, and a membership-based model, and is expected to grow Chewy Vet Care from 18 to 47 locations nationwide while adding more than $125 million in annualized run-rate revenue. - learn more
      • Honk has been acquired by Frontenac, with the Los Angeles roadside assistance software company simultaneously completing an add-on acquisition of CurbsideSOS as part of the deal. The combination is meant to scale Honk’s platform for roadside assistance, towing, and accident management, with former Grubhub executives including Adam DeWitt, Matt Maloney, and Eric Ferguson joining the company to lead its next phase of growth. - learn more

      Download the dot.LA App

      RELATEDEDITOR'S PICKS
      Trending